Jonas Kath

This paper develops a non-viral CRISPR/Cas9 HDR platform for stable transgene knock-in in solid tumor models, achieving up to 60% efficiency in neuroblastoma cells.

This paper develops gene-edited tacrolimus-resistant Treg cells (FKBP12KO-Treg) for clinical use in transplant recipients, showing they maintain immunoregulatory function while resisting tacrolimus.

This study shows that unmodified mRNA can be used for CAR-T cell engineering without compromising function, eliminating the need for costly nucleoside modifications.

This paper develops CancerPAM, a bioinformatics pipeline for identifying CRISPR knock-in sites to remodel the tumor microenvironment, enhancing CAR T cell therapy in solid tumors.

This study shows that matching or engineering HLA-I and HLA-II improves the efficacy of allogeneic regulatory T cells for immunoregulation.

This paper develops BEKI, a base editor-based method for targeted transgene insertion and multiplex gene disruption in T cells, reducing chromosomal translocations compared to Cas9-based approaches.

This paper introduces one-pot PASTA, a non-viral method for efficient large transgene integration in human T cells using CRISPR and integrases, showing improved performance over existing methods.

This study improves CRISPR-Cas12a knock-in efficiency in human T cells by using single-stranded DNA templates with double-stranded Cas-target-sequences, achieving up to 90% knock-in rates for transgene inserts.

This paper develops a non-viral CRISPR-Cas12a method to redirect Tregs with CARs by integrating an antigen-binding domain into the CD3 epsilon gene, showing improved antigen-specific function and graft protection in a mouse model.

This paper develops a method to integrate ζ-deficient CARs into the CD3ζ gene to create functional CAR-T and CAR-NK cells with improved safety and efficacy for off-the-shelf therapies.